Pfizer-BioNTech has detected high efficacy levels in its anticipated booster dose version of COVID-19 vaccine following a phase three clinical trial.
The biopharmaceutical companies announced on Thursday that a controlled trial evaluating the efficacy and safety of booster dose in more than 10,00
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
